Literature DB >> 1540262

Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis.

L W Terstappen1, M Safford, S Könemann, M R Loken, K Zurlutter, T Büchner, W Hiddemann, B Wörmann.   

Abstract

The frequency and distribution of aberrant antigen expression are analyzed on bone marrow aspirates from 80 patients with newly diagnosed acute myeloid leukemia (AML) by multidimensional flow cytometry. Parameters examined are the light scatter profile of the leukemic cells and the correlative expression of different combinations of the CD2, 4, 5, 7, 11b, 11c, 13, 14, 15, 16, 33, 34, 38, and HLA-DR antigens. Antigen expression on leukemic cells in bone marrow is described by characteristic antigen expression patterns describing: (i) the percentage of cells expressing the antigen; (ii) the antigen density; and (iii) the distribution of the antigen on the leukemic cells. Typically the non-myeloid antigens are homogeneously expressed by the leukemic cells, whereas the myeloid associated antigen CD11b, CD11c, CD14, and CD15 are heterogeneously expressed. Comparison of the antigenic profiles of 80 bone marrow aspirates revealed an extreme interclonal heterogeneity. Comparison of the antigen expression patterns found in AML patients with the antigen expression in normal bone marrow revealed four patterns of aberrant antigen expression in AML: (i) expression of nonmyeloid antigens (i.e. CD2, CD5, and CD7 were present in 57, 60, and 37% of the patients, respectively); (ii) asynchronous expression of myeloid associated antigens (i.e. co-expression of CD34 and CD15 in 25% of the patients and expression of CD16 on immature myeloid cells in 15% of the cases); (iii) over-expression of myeloid associated antigens (e.g. CD34 in 16% of the cases and CD14 on neutrophilic cells in 19% of all patients); and (iv) absence of expression of myeloid associated antigens (e.g. lack of CD33 in 21% of the cases and lack of both CD11b and CD15 in 6% of all patients. Multidimensional flow cytometric analysis of bone marrow aspirates of AML patients disclosed that the leukemic cells of each AML patient had a unique antigenic profile and could be discriminated from their normal counterparts based on aberrant antigen expression and typical light scatter profiles. The ability to distinguish leukemic cells from normal cells allows the detection of residual leukemic cells during and after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540262

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

Review 1.  Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.

Authors:  J M Jaso; S A Wang; J L Jorgensen; P Lin
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

Review 2.  Methods of Detection of Measurable Residual Disease in AML.

Authors:  Yi Zhou; Brent L Wood
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 3.  Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC).

Authors:  A Nagler; R Condiotti; R Rabinowitz; M Schlesinger; M Nguyen; L W Terstappen
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

4.  Integrated analysis of proteome, phosphotyrosine-proteome, tyrosine-kinome, and tyrosine-phosphatome in acute myeloid leukemia.

Authors:  Jiefei Tong; Mohamed Helmy; Florence M G Cavalli; Lily Jin; Jonathan St-Germain; Robert Karisch; Paul Taylor; Mark D Minden; Michael D Taylor; Benjamin G Neel; Gary D Bader; Michael F Moran
Journal:  Proteomics       Date:  2017-03       Impact factor: 3.984

5.  Universal monitoring of minimal residual disease in acute myeloid leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Sheila Shurtleff; Allen Eng-Juh Yeoh; Wee Joo Chng; Siew Peng Chen; Jeffrey E Rubnitz; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  JCI Insight       Date:  2018-05-03

Review 6.  Microfluidic microscopy-assisted label-free approach for cancer screening: automated microfluidic cytology for cancer screening.

Authors:  Veerendra Kalyan Jagannadh; G Gopakumar; Gorthi R K Sai Subrahmanyam; Sai Siva Gorthi
Journal:  Med Biol Eng Comput       Date:  2016-07-22       Impact factor: 2.602

Review 7.  Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Authors:  Akihiro Takeshita
Journal:  Int J Hematol       Date:  2013-05-26       Impact factor: 2.490

Review 8.  Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.

Authors:  Suraj Pratap; Zhizhuang J Zhao
Journal:  Cancer Rep (Hoboken)       Date:  2020-01-08

9.  Characterization of aberrant phenotypes in acute myeloblastic leukemia.

Authors:  A Macedo; A Orfão; M B Vidriales; M C López-Berges; B Valverde; M González; M D Caballero; F Ramos; M Martínez; J Fernández-Calvo
Journal:  Ann Hematol       Date:  1995-04       Impact factor: 3.673

10.  Aberrant myeloid antigen co-expression is correlated with high percentages of CD34-positive cells among blasts of acute lymphoblastic leukemia patients: an Indian tertiary care center perspective.

Authors:  Rahul Kumar Sharma; Abhishek Purohit; Venkatesan Somasundaram; Pravas Chandra Mishra; Mrinalini Kotru; Ravi Ranjan; Sunil Kumar; Sudha Sazawal; Hara Prasad Pati; Seema Tyagi; Renu Saxena
Journal:  Blood Res       Date:  2014-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.